You are here
Drugmaker AstraZeneca pushes to protect Crestor from generic competition
NO more than a few hundred US children have a rare disease characterised by ultra-high levels of bad cholesterol. Yet, to the giant drugmaker AstraZeneca, this small group could be worth billions of dollars.
The company is making a bold attempt to fend off impending
- CALL +65 6388 3838
- EMAIL email@example.com